Is it more cost-effective to use bevacizumab in the primary treatment setting or at recurrence? An economic analysis

Journal article

Peer reviewed

K. Fuh, J. Chan, B. Monk, R. Urban, L. Hu, D. Kapp, A. Caughey and X. Yu

Gynecologic oncology, Vol.120, pp.S98-S98

03/01/2011

Metrics

6 Record Views

Title: Is it more cost-effective to use bevacizumab in the primary treatment setting or at recurrence? An economic analysis
Creators: K. Fuh - UCSF Helen Diller Family Comprehensive Cancer Center
J. Chan - UCSF Helen Diller Family Comprehensive Cancer Center
B. Monk - Creighton University
R. Urban - UCSF Helen Diller Family Comprehensive Cancer Center
L. Hu - UCSF Helen Diller Family Comprehensive Cancer Center
D. Kapp - Stanford Medicine
A. Caughey - UCSF Helen Diller Family Comprehensive Cancer Center
X. Yu - University of Memphis
Publication Details: Gynecologic oncology, Vol.120, pp.S98-S98
Publisher: Elsevier Inc
Identifiers: 991005969070202656
Academic Unit: Obstetrics & Gynecology
Language: English
Resource Type: Journal article